By inhibiting the inflammatory responses mediated by cytokines like TNF-α, IFN-γ, and IL-6, it may be possible to mitigate the neuroinflammatory processes that contribute to AD pathology (Jiang et al. 2019; Dhapola et al. 2021). This evidence concerns the gene IL6 and Alzheimer disease.